Beyond levodopa, two other classes of antiparkinsonian medication shape Parkinson's treatment: dopamine agonists and MAO-B inhibitors. Both are particularly valuable in early disease, especially in younger patients where delaying levodopa initiation can postpone the motor complications that emerge after years of levodopa therapy.
- Class
- Dopamine agonists + MAO-B inhibitors
- Mechanism
- Dopamine agonists: directly activate D2/D3 receptors. MAO-B inhibitors: prevent dopamine breakdown by MAO-B isoform (selective for B reduces dietary/drug interactions vs nonselective MAOIs).
- Typical dose
- Pramipexole 0.125-1.5 mg TID; ropinirole 0.25-8 mg TID; rasagiline 0.5-1 mg daily
- FDA indications
- Parkinson's disease (monotherapy early disease or adjunct to levodopa)
- Key adverse effects
- Dopamine agonists: somnolence/sudden sleep attacks, impulse control disorders (gambling, hypersexuality — well-documented), edema, hallucinations. MAO-B inhibitors: generally well-tolerated; rare hypertensive episodes; drug interactions (avoid with serotonergic agents).
- Representative agents
- Dopamine agonists: pramipexole (Mirapex), ropinirole (Requip), rotigotine patch (Neupro), apomorphine. MAO-B inhibitors: selegiline (Eldepryl), rasagiline (Azilect), safinamide (Xadago).
Dopamine agonists useful in younger patients (delays levodopa motor complications); impulse control disorders require explicit counseling at prescription. MAO-B inhibitors well-tolerated, often used as adjunct or early monotherapy. Rasagiline may have modest neuroprotective signal.
Dopamine agonists — pramipexole (Mirapex), ropinirole (Requip), rotigotine patch (Neupro), apomorphine. Direct D2/D3 receptor activation, bypassing the need for endogenous dopamine production. Longer half-lives than levodopa, smoother symptom coverage, less risk of motor fluctuations long-term. The trade-off is more risk of impulse control disorders — pathological gambling, hypersexuality, compulsive shopping, binge eating — at rates of 10-15 percent. Counsel every patient and family at prescription; ask at every follow-up. Other side effects: somnolence (sudden sleep attacks have been reported), edema, hallucinations especially in older patients.
Dopamine agonists and MAO-B inhibitors support dopaminergic transmission in Parkinson's disease through routes that bypass or supplement levodopa.
Mechanism note: Dopamine agonists and MAO-B inhibitors supplement dopaminergic transmission in Parkinson's — the agonists' impulse-control disorder risk is the single most important psychiatric crossover to screen for.
MAO-B inhibitors — selegiline (Eldepryl), rasagiline (Azilect), safinamide (Xadago). Selectively inhibit MAO-B (which preferentially metabolizes dopamine), prolonging endogenous dopamine signaling. Selectivity at therapeutic doses avoids the tyramine reaction of nonselective MAOIs — fewer dietary restrictions. Well-tolerated, modest motor benefit, sometimes proposed neuroprotection (the evidence is suggestive but not conclusive).
Drug interaction caution with MAO-B inhibitors: avoid combination with serotonergic agents (SSRIs, SNRIs, tramadol) — serotonin syndrome risk. Co-prescription with SSRIs requires careful screening; some clinicians use specific MAO-B inhibitors with selected SSRIs cautiously, but the general rule is avoidance.
For early Parkinson's in a younger patient, starting with a dopamine agonist or MAO-B inhibitor delays levodopa and reduces long-term motor complications. As disease progresses, levodopa is eventually added; the earlier agents can continue as adjuncts.
- Cost
- Pramipexole/ropinirole generic ~$15-40/month. Rotigotine patch (Neupro) brand-only ~$400+/month. Selegiline/rasagiline generic ~$30-100/month. Safinamide (Xadago) brand-only ~$1,000+/month.
- Generic status
- Most oral agents generic. Patches and newer agents brand-only.
- Formulary typical
- Generics: Tier 1-2. Brand patches and newer MAO-B inhibitors: PA.
- Access friction
- Generic oral agents easy. Patches and safinamide PA often.
Prescriber tip: For early Parkinson's, generic dopamine agonist or MAO-B inhibitor is accessible. Counsel impulse control disorders explicitly at prescription — these emerge insidiously.
Match the strategy to the patient's age, disease severity, and tolerability profile.